Karyopharm Therapeutics Inc. (NASDAQ:KPTI) has been given a $18.00 price objective by equities researchers at Cantor Fitzgerald in a report released on Thursday. The brokerage currently has a “buy” rating on the stock. Cantor Fitzgerald’s price target indicates a potential upside of 58.17% from the company’s current price.
A number of other equities research analysts have also weighed in on KPTI. Robert W. Baird reaffirmed an “outperform” rating and set a $15.00 target price on shares of Karyopharm Therapeutics in a research report on Tuesday, July 4th. Zacks Investment Research raised Karyopharm Therapeutics from a “hold” rating to a “buy” rating and set a $11.00 target price for the company in a research report on Thursday, July 6th. Jefferies Group LLC reaffirmed a “buy” rating and set a $16.00 target price on shares of Karyopharm Therapeutics in a research report on Friday, July 14th. BidaskClub lowered Karyopharm Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Monday, July 31st. Finally, Canaccord Genuity set a $18.00 target price on Karyopharm Therapeutics and gave the company a “buy” rating in a research report on Tuesday, August 8th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and seven have given a buy rating to the company. Karyopharm Therapeutics currently has an average rating of “Buy” and an average price target of $15.38.
Karyopharm Therapeutics (NASDAQ KPTI) traded up 1.93% during trading on Thursday, reaching $11.60. The company’s stock had a trading volume of 237,776 shares. The company’s market capitalization is $546.80 million. Karyopharm Therapeutics has a 12-month low of $6.27 and a 12-month high of $14.63. The firm’s 50-day moving average price is $10.66 and its 200 day moving average price is $9.90.
Karyopharm Therapeutics (NASDAQ:KPTI) last issued its earnings results on Tuesday, August 8th. The company reported ($0.64) earnings per share for the quarter, meeting the Zacks’ consensus estimate of ($0.64). Karyopharm Therapeutics had a negative return on equity of 70.42% and a negative net margin of 67,267.47%. The company’s quarterly revenue was down 95.0% on a year-over-year basis. During the same quarter last year, the firm posted ($0.84) earnings per share. On average, analysts predict that Karyopharm Therapeutics will post ($2.67) earnings per share for the current fiscal year.
In other news, Director Mansoor Raza Mirza sold 2,882 shares of the business’s stock in a transaction on Friday, September 15th. The stock was sold at an average price of $11.00, for a total value of $31,702.00. Following the completion of the transaction, the director now directly owns 2,882 shares of the company’s stock, valued at approximately $31,702. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Over the last three months, insiders sold 10,695 shares of company stock valued at $118,950. Corporate insiders own 14.71% of the company’s stock.
Several institutional investors and hedge funds have recently added to or reduced their stakes in KPTI. Voya Investment Management LLC raised its position in shares of Karyopharm Therapeutics by 42.1% in the 2nd quarter. Voya Investment Management LLC now owns 15,008 shares of the company’s stock worth $136,000 after acquiring an additional 4,444 shares in the last quarter. Tudor Investment Corp ET AL bought a new position in shares of Karyopharm Therapeutics in the 2nd quarter worth $136,000. Trexquant Investment LP bought a new position in shares of Karyopharm Therapeutics in the 2nd quarter worth $202,000. American International Group Inc. raised its position in shares of Karyopharm Therapeutics by 20.9% in the 1st quarter. American International Group Inc. now owns 16,422 shares of the company’s stock worth $211,000 after acquiring an additional 2,836 shares in the last quarter. Finally, State of Wisconsin Investment Board bought a new position in shares of Karyopharm Therapeutics in the 2nd quarter worth $235,000. 58.97% of the stock is owned by hedge funds and other institutional investors.
About Karyopharm Therapeutics
Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. It has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1.
Receive News & Ratings for Karyopharm Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.